1. Murphy SL KK, Xu JQ, Arias E. Mortality in the United States, 2023. NCHS Data Brief, no 521. Hyattsville, MD: National Center for Health Statistics. 2024. 
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-263.
3. Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: A comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol 2025;16:607.
4. Johdi NA, Sukor NF. Colorectal cancer immunotherapy: Options and strategies. Front Immunol 2020;11:1624.
5. Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun (Lond) 2022;42:88-116.
6. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. cancer cell. 2020;37:496-513.
7. Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 2020;5:8.
8. Cotruvo JA, Jr. The chemistry of lanthanides in biology: Recent discoveries, emerging principles, and technological applications. ACS Cent Sci 2019;5:1496-1506.
9. Cotton S. The Lanthanides-Principles and Energetics. In Lanthanide and Actinide Chemistry, S. Cotton Ed. 2026. https://doi.org/10.1002/0470010088.ch2
10. Coordination Chemistry of the Lanthanides.  Lanthanide and Actinide Chemistry2006. p. 35-60.
11. Gahlaut N, Miller LW. Time-resolved microscopy for imaging lanthanide luminescence in living cells. Cytometry Part A. 2010;77A:1113-1125.
12. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem Rev 1999;99:2293-2352.
13. Bünzli JC. Lanthanide luminescence for biomedical analyses and imaging. Chem Rev 2010;110:2729-2755.
14. Sedgwick AC, Brewster JT, Harvey P, Iovan DA, Smith G, He XP, et al. Metal-based imaging agents: Progress towards interrogating neurodegenerative disease. Chem Soc Rev 2020;49:2886-2915.
15. Bünzli J-CG, Piguet C. Taking advantage of luminescent lanthanide ions. Chem Soc Rev2005;34:1048-1077.
16. The Lanthanide Elements and Simple Binary Compounds.  Lanthanide and Actinide Chemistry2006. p. 23-33.
17. Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS. Radiometals for combined imaging and therapy. Chem Rev 2013;113:858-883.
18. Cotruvo JA, Jr. The chemistry of lanthanides in biology: Recent discoveries, emerging principles, and technological applications. ACS Cent Sci 2019;5:1496-1506.
19. Forte A, Gago S, Alves C, Silva J, Alves J, Pedrosa R, et al. Lanthanide-based organic salts: Synthesis, characterization, and cytotoxicity studies. Molecules 2023;28:7152.
20. Mejia-Mendez JL, Reza-Zaldívar EE, Sanchez-Martinez A, Ceballos-Sanchez O, Navarro-López DE, Marcelo Lozano L, et al. Exploring the cytotoxic and ant-ioxidant properties of lanthanide-doped ZnO nanoparticles: A study with machine learning interpretation. J Nanobiotechnology 2024;22:687.
21. Han S, Liu Y, Cai T, Liu Y, Ge-Zhang S. Lanthanide nanotheranostics in radiotherapy. Int J Mol Sci 2026;27:426.
22. Costanzo M, Bianco S, Fik-Jaskółka M, Roviello GN. Recent advances in lanthanide complexes in biological systems: Coordination principles and interactions with biomolecules. Int J Mol Sci 2026;27:1566.
23. Li L, Tong R, Li M, Kohane DS. Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy. Acta Biomater 2016;33:34-39.
24.    Henderson L, Neumann O, Kadria-Vili Y, Gerislioglu B, Bankson J, Nordlander P, et al. Plasmonic gadolinium oxide nanomatryoshkas: Bifunctional magnetic resonance imaging enhancers for photothermal cancer therapy. PNAS Nexus 2022;1:pgac140.
25. Jiang Q, Liu L, Li Q, Cao Y, Chen D, Du Q, et al. NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer. J Nanobiotechnology 2021;19:64.
26. Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI contrast agents: Current challenges and new frontiers. Chem Rev 2019;119:957-1057.
27. Kamaly N, Miller A, Bell J. Chemistry of tumour targeted T1 based MRI contrast agents. Curr Top Med Chem 2010;10:1158-1183.
28. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-264.
29. Mi P, Kokuryo D, Cabral H, Kumagai M, Nomoto T, Aoki I, et al. Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Control Release 2014;174:63-71.
30. Harvey HB, Gowda V, Cheng G. Gadolinium deposition disease: a new risk management threat. J Am Coll Radiol 2020;17:546-550.
31. Rahman M. Magnetic resonance imaging and iron-oxide nanoparticles in the era of personalized medicine. Nanotheranostics 2023;7:424-449.
32. Gale EM, Caravan P. Gadolinium-free contrast agents for magnetic resonance imaging of the central nervous system. ACS Chem Neurosci 2018;9:395-397.
33. Zhang T, Deng M, Zhang L, Liu Z, Liu Y, Song S, et al. Facile synthesis of holmium-based nanoparticles as a CT and MRI dual-modal imaging for cancer diagnosis. Front Oncol 2021;11:741383. 
34. Wan S, Cui F, Li B, Zhao K, He H, Zhang Y, et al. Dysprosium-modified gold nanoparticles as T2ex contrast agents for magnetic resonance imaging. ACS Appl. Nano Mater 2020;3:9433-9439.
35. Mishra SK, Kannan S. A bimetallic silver-neodymium theranostic nanoparticle with multimodal NIR/MRI/CT imaging and combined chemo-photothermal therapy. Inorg Chem 2017;56:12054-12066.
36. Asadollahzade E, Ghadiri F, Ebadi Z, Moghadasi AN. The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients. Rev Assoc Med Bras (1992). 2022;68:979-981.
37. Mortezazadeh T, Gholibegloo E, Riyahi Alam N, Haghgoo S, Musa AE, Khoobi M. Glucosamine conjugated gadolinium (III) oxide nanoparticles as a novel targeted contrast agent for cancer diagnosis in MRI. J Biomed Phys Eng 2020;10:25-38.
38. Ravoori MK, Singh S, Bhavane R, Sood AK, Anvari B, Bankson J, et al. Multimodal magnetic resonance and near-infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode-dual-gadolinium liposomal contrast agent. Sci Rep 2016;6:38991.
39. Leif RC, Vallarino LM, Becker MC, Yang S. Increasing the luminescence of lanthanide complexes. Cytometry Part A 2006;69A:767-778.
40. Lengacher R, Martin KE, Śmiłowicz D, Esseln H, Lotlikar P, Grichine A, et al. Targeted, molecular europium((III)) probes enable luminescence-guided surgery and 1 photon post-surgical luminescence microscopy of solid tumors. J Am Chem Soc 2023;145:24358-24366.
41. Gómez-Morales J, Verdugo-Escamilla C, Fernández-Penas R, Parra-Milla CM, Drouet C, Maube-Bosc F, et al. Luminescent biomimetic citrate-coated europium-doped carbonated apatite nanoparticles for use in bioimaging: physico-chemistry and cytocompatibility. RSC Adv 2018;8:2385-2397.
42. Chen G, Qiu H, Prasad PN, Chen X. Upconversion nanoparticles: Design, nanochemistry, and applications in theranostics. Chem Rev 2014;114:5161-5214.
43. Dang Y, Liu X, Zheng Z, Wang A, Huang Y, Luo Z, et al. Lutetium-based nanoprobes for radiosensitization with immune microenvironment remodeling and NIR-II fluorescence imaging-guided surgery in colorectal cancer. Adv Sci (Weinh) 2025;12:e10136.
44. Duan G, Zhang J, Wei Z, Wang X, Zeng J, Wu S, et al. Intraoperative diagnosis of early lymphatic metastasis using neodymium-based rare-earth NIR-II fluorescence nanoprobe. Nanoscale Adv 2023;5:4240-4249.
45. Peng T, Pu R, Wang B, Zhu Z, Liu K, Wang F, et al. The spectroscopic properties and microscopic imaging of thulium-doped upconversion nanoparticles excited at different NIR-II light. Biosensors (Basel) 2021;11:148.
46. Gnach A, Lipinski T, Bednarkiewicz A, Rybka J, Capobianco JA. Upconverting nanoparticles: assessing the toxicity. Chem Soc Rev 2015;44:1561-1584.
47. Ren F, Huang H, Yang H, Xia B, Ma Z, Zhang Y, et al. Tailoring near-infrared-IIb fluorescence of thulium(III) by nanocrystal structure engineering. Nano Lett 2023;23:10058-10065.
48. Wang T, Wang S, Liu Z, He Z, Yu P, Zhao M, et al. A hybrid erbium(III)-bacteriochlorin near-infrared probe for multiplexed biomedical imaging. Nat Mater 2021;20:1571-1578.
49. Webster B, Ivanov P, Russell B, Collins S, Stora T, Ramos JP, et al. Chemical purification of terbium-155 from pseudo-isobaric impurities in a mass separated source produced at CERN. Sci Rep 2019;9:10884.
50. Cassells I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T, et al. Radiolabeling of human serum albumin with terbium-161 using mild conditions and evaluation of in vivo stability. Front Med (Lausanne) 2021;8:675122.
51. Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, et al. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with (152)Tb-DOTATOC. Dalton Trans 2017;46:14638-14646.
52. Aluicio-Sarduy E, Thiele NA, Martin KE, Vaughn BA, Devaraj J, Olson AP, et al. Establishing radiolanthanum chemistry for targeted nuclear medicine applications. Chemistry 2020;26:1238-1242.
53. Vermeulen K, Van de Voorde M, Segers C, Coolkens A, Rodriguez Pérez S, Daems N, et al. Exploring the potential of high-molar-activity samarium-153 for targeted radionuclide therapy with [(153)Sm]Sm-DOTA-TATE. Pharmaceutics 2022;14:2566.
54. Muftuoglu M, Andreeff M. Sample multiplexing in CyTOF: Path to optimize single-cell proteomic profiling. Cell Signal (Middlet) 2024;2:113-119.
55. Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al. First-in-humans application of 161Tb: A feasibility study using 161Tb-DOTATOC. J Nucl Med 2021;62:1391-1397.
56. Xu J, Zhou S, Tu D, Zheng W, Huang P, Li R, et al. Sub-5 nm lanthanide-doped lutetium oxyfluoride nanoprobes for ultrasensitive detection of prostate specific antigen. Chem Sci 2016;7:2572-2578.
57. Gidwani K, Nadeem N, Huhtinen K, Kekki H, Heinosalo T, Hynninen J, et al. Europium nanoparticle-based Sialyl-Tn monoclonal antibody discriminates epithelial ovarian cancer-associated CA125 from benign sources. J Appl Lab Med 2019;4:299-310.
58. Liu C, Lu S, Yang L, Chen P, Bai P, Wang Q. Near-infrared neodymium Tag for quantifying targeted biomarker and counting its host circulating tumor cells. Anal Chem 2017;89:9239-9246.
59. Lian X, Chen F, Zhang Y, Zhang J, Yao B, Niu H. A ratio luminescent europium organometallic gel for in vitro detection of hepatocellular carcinoma marker and cellular imaging. Talanta 2025;288:127708.
60. Wang M, Hu M, Hu B, Guo C, Song Y, Jia Q, et al. Bimetallic cerium and ferric oxides nanoparticles embedded within mesoporous carbon matrix: Electrochemical immunosensor for sensitive detection of carbohydrate antigen 19-9. Biosens Bioelectron 2019;135:22-29.
61. Mishra UK, Srivastava S, Singh KR, Kumar A, Singh V, Mishra DP, et al. A bio-nano-engineered platform fabricated from cerium oxide-carbon nanoparticles stabilized with chitosan for label-free sensing of a lung cancer biomarker. Anal Methods 2025;17:349-359.
62. Parihar A, Vishwakarma P, Prajapati P, Khan R. Non-invasive ultra-sensitive detection of breast cancer biomarker using cerium nanoparticle functionalized graphene oxide enabled impedimetric aptasensor. Biosens Bioelectron 2025;268:116925.
63. Cabrero-Martín A, Santiago S, Serafín V, Pedrero M, Montero-Calle A, Pingarrón JM, et al. Multifunctional cerium nanolabels in electrochemical immunosensing with improved robustness and performance: determination of TIM-1 in colorectal cancer scenarios as a case study. Mikrochim Acta 2025;192:243.
64. Fan D, Ren X, Wang H, Wu D, Zhao D, Chen Y, et al. Ultrasensitive sandwich-type photoelectrochemical immunosensor based on CdSe sensitized La-TiO(2) matrix and signal amplification of polystyrene@Ab(2) composites. Biosens Bioelectron 2017;87:593-599.
65. Tiwari S, Gupta PK, Bagbi Y, Sarkar T, Solanki PR. L-cysteine capped lanthanum hydroxide nanostructures for non-invasive detection of oral cancer biomarker. Biosens Bioelectron 2017;89:1042-1052.
66. Teo RD, Termini J, Gray HB. Lanthanides: Applications in cancer diagnosis and therapy. J Med Chem 2016;59:6012-6024.
67. Nikolova V, Kircheva N, Dobrev S, Angelova S, Dudev T. Lanthanides as calcium mimetic species in calcium-signaling/buffering proteins: The effect of lanthanide type on the Ca2+/Ln3+ Competition. Int J Mol Sci 2023;24:6297.
68. Chundawat NS, Jadoun S, Zarrintaj P, Chauhan NPS. Lanthanide complexes as anticancer agents: A review. Polyhedron 2021;207:115387.
69. Wang H, Ren G, Xu Y, Deng R, Wang R, Zhou L. Novel erbium complex with anticancer activity against radiation resistant lung adenocarcinoma cells. J Inorg Biochem 2025;269:112902.
70. Safwat G, Soliman ESM, Mohamed HRH. Induction of ROS mediated genomic instability, apoptosis and G0/G1 cell cycle arrest by erbium oxide nanoparticles in human hepatic Hep-G2 cancer cells. Sci Rep 2022;12:16333.
71. Zhang H, Zhang W, Hu B, Qin X, Yi T, Ye Y, et al. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles. J Nanobiotechnology 2023;21:117.
72. Yarramala DS, Prakash P, Ranade DS, Doshi S, Kulkarni PP, Bhaumik P, et al. Cytotoxicity of apo bovine α-lactalbumin complexed with La(3+) on cancer cells supported by its high resolution crystal structure. Sci Rep 2019;9:1780.
73. Zakharova LY, Voloshina AD, Ibatullina MR, Zhiltsova EP, Lukashenko SS, Kuznetsova DA, et al. Self-assembling metallocomplexes of the amphiphilic 1,4-Diazabicyclo[2.2.2]octane derivative as a platform for the development of nonplatinum anticancer drugs. ACS Omega 2022;7:3073-3082.
74. Xu K, Chang M, Wang Z, Yang H, Jia Y, Xu W, et al. Multienzyme-mimicking LaCoO(3) nanotrigger for programming cancer-cell pyroptosis. Adv Mater 2023;35:e2302961.
75. Saha B, Ghosh A, Singh A, Sahu SK. Amplification of luminescence intensity by ytterbium(III) dopant in upconversion nanoparticles integrated with carbon dots for NIR-responsive targeted photodynamic therapy. Dalton Trans 2025;54:13071-13084.
76. Zheng X, Zhong J, Dong MY, Wen Y, Chen AZ. Synthesis of porphyrin-based 2D ytterbium metal organic frameworks for efficient photodynamic therapy. RSC Adv 2022;12:34318-34324.
77.    Lim K, Kim HK, Le XT, Nguyen NT, Lee ES, Oh KT, et al. Highly red light-emitting erbium- and lutetium-doped core-shell upconverting nanoparticles surface-modified with PEG-folic acid/TCPP for suppressing cervical cancer HeLa cells. Pharmaceutics 2020;12:1102.
78. Obitz D, Gkika KS, Heller M, Keyes TE, Metzler-Nolte N. A phototoxic thulium complex exhibiting intracellular ROS production upon 630 nm excitation in cancer cells. Chem Commun (Camb) 2023;59:1943-1946.
79. Ung P, Clerc M, Huang H, Qiu K, Chao H, Seitz M, et al. Extending the excitation wavelength of potential photosensitizers via appendage of a kinetically stable Terbium(III) macrocyclic complex for applications in photodynamic therapy. Inorg Chem 2017;56:7960-7974.
80. Li M, Liu J, Luo X, Zhao Z, Wang S, Liu Z, et al. Monoclonal antibody-guided tumor-targeted hollow virus-like cerium oxide with oxygen self-supply for intensifying photodynamic therapy. Adv Healthc Mater 2023;12:e2202418.
81. Fan Y, Li P, Hu B, Liu T, Huang Z, Shan C, et al. A smart photosensitizer-cerium oxide nanoprobe for highly selective and efficient photodynamic therapy. Inorg Chem 2019;58:7295-7302.
82. Atif M, Iqbal S, Fakhar EAM, Ismail M, Mansoor Q, Mughal L, et al. Manganese-doped cerium oxide nanocomposite induced photodynamic therapy in MCF-7 cancer cells and antibacterial activity. Biomed Res Int 2019;2019:7156828.
83. Kornienko AI, Teplonogova MA, Shevelyova MP, Popkov MA, Popov AL, Ivanov VE, et al. Novel flavin mononucleotide-functionalized cerium fluoride nanoparticles for selective enhanced X-ray-induced photodynamic therapy. J Funct Biomater 2024;15:373.
84. Daouk J, Iltis M, Dhaini B, Béchet D, Arnoux P, Rocchi P, et al. Terbium-based AGuIX-design nanoparticle to mediate X-ray-induced photodynamic therapy. Pharmaceuticals (Basel) 2021;14:396.
85. Maiti D, Yu H, Mochida Y, Won S, Yamashita S, Naito M, et al. Terbium-rose bengal coordination nanocrystals-induced ROS production under low-dose X-rays in cultured cancer cells for photodynamic therapy. ACS Appl Bio Mater 2023;6:2505-2513.
86. Tang S, Huang W, Gao Y, An N, Wu Y, Yang B, et al. Low-work-function LaB(6) for realizing photodynamic-enhanced photothermal therapy. J Mater Chem B 2021;9:4380-4389.
87. Zeng L, Cheng H, Dai Y, Su Z, Wang C, Lei L, et al. In vivo regenerable cerium oxide nanozyme-loaded pH/H2O2-responsive nanovesicle for tumor-targeted photothermal and photodynamic therapies. ACS Appl Mater Interfaces 2021;13:233-244.
88. Truong TT, Doan VHM, Nguyen DQ, Nguyen QD, Choi J, Subramaniyan B, et al. Synergistic therapeutic effects of prussian blue erbium-doped hydroxyapatite nanoparticles in photothermal photodynamic cancer therapy. ACS Biomater Sci Eng 2025;11:2639-2652.
89. Zuo YC, Huo CM, Chen Y, Ding PL, Tong SY, Xue W, et al. Cancer-thylakoid hybrid membrane camouflaged thulium oxide nanoparticles with oxygen self-supply capability for tumor-homing phototherapy. Adv Healthc Mater.2024;13:e2303779.
90. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091-1103.
91. Chandran E, Figg WD, Madan R. Lutetium-177-PSMA-617: A vision of the future. Cancer Biol Ther 2022;23:186-190.
92. de Souza ZS, Xavier CB, Gomes LBM, de Medeiros MFB, de Sousa MC, Pereira AAL, Marin JFG, Buchpiguel CA, Costa FP. Survival and response outcomes for gastrointestinal neuroendocrine tumor (GEP-NETs) patients treated with lutetium-177-DOTATATE in a brazilian reference center: A six-year follow-up experience. Cancers (Basel). 2023;15:4506.
93. Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, et al. Phase 2 study of Lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol 2016;69:767-770.
94. Giri S, Allen KJH, Prabaharan CB, Ramirez JB, Fiore L, Uppalapati M, et al. Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma. Nucl Med Biol 2024;134-135:108917.
95. Nguyen H, Hird K, Cardaci J, Smith S, Lenzo NP. Lutetium-177 labelled anti-PSMA monoclonal antibody (Lu-TLX591) therapy for metastatic prostate cancer: Treatment toxicity and outcomes. Mol Diagn Ther 2024;28:291-299.
96. Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, et al. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget 2016;7:69014-69023.
97. Wong YH, Kasbollah A, Abdullah BJJ, Yeong CH. Facile preparation of samarium carbonate-polymethacrylate microspheres as a neutron-activatable radioembolic agent for hepatic radioembolization. Pharmaceutics 2023;15:877.
98. Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Acharya RU, Yeong CH. Neutron-activated biodegradable samarium-153 acetylacetonate-poly-L-lactic acid microspheres for intraarterial radioembolization of hepatic tumors. World J Exp Med 2020;10:10-25.
99. Schulze-Zachau V, Verset G, De Bondt P, De Keukeleire K, Gühne F, Heuschkel M, et al. Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data. Front Oncol 2024;14:1404621.
100. Bagheri R, Ranjbar H. Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies. Asia Ocean J Nucl Med Biol 2025;13:94-101.
101.    Morsink NC, Nijsen JFW, Grinwis GCM, Hesselink JW, Kirpensteijn J, van Nimwegen SA. Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs. Front Vet Sci 2022;9:1015248.
102. Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging 2019;46:1919-1930.
103.    Talip Z, Borgna F, Müller C, Ulrich J, Duchemin C, Ramos JP, et al. Production of mass-separated Erbium-169 towards the first preclinical in vitro investigations. Front Med (Lausanne) 2021;8:643175.
104. Matsumoto K, Saitoh H, Doan TLH, Shiro A, Nakai K, Komatsu A, et al. Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. Sci Rep 2019;9:13275.
105. Garcia-Prada CD, Carmes L, Atis S, Parach A, Bertolet A, Jarlier M, et al. Gadolinium-based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy. J Nucl Med 2023;64:1956-1964.
106. Li F, Li Z, Jin X, Liu Y, Zhang P, Li P, et al. Ultra-small gadolinium oxide nanocrystal sensitization of non-small-cell lung cancer cells toward X-ray irradiation by promoting cytostatic autophagy. Int J Nanomedicine 2019;14:2415-2431.
107. Zamyatina EA, Goryacheva OA, Popov AL, Popova NR. Novel pyrroloquinoline quinone-modified cerium oxide nanoparticles and their selective cytotoxicity under X-ray irradiation. Antioxidants (Basel) 2024;13:1445.
108. Chukavin NN, Filippova KO, Ermakov AM, Karmanova EE, Popova NR, Anikina VA, et al. Redox-active cerium fluoride nanoparticles selectively modulate cellular response against X-ray irradiation in vitro. Biomedicines 2023;12:11.
109. Ryabtseva MS, Filimonova MV, Filimonov AS, Soldatova OV, Shitova AA, Rybachuk VA, et al. Polyacrylic acid-coated LaB(6) nanoparticles as efficient sensitizers for binary proton therapy. Pharmaceutics 2025;17:515.
110.    Li T, Zhang Y, Li C, Song Y, Jiang T, Yin Y, et al. Microbial photosynthetic oxygenation and radiotherapeutic sensitization enables pyroptosis induction for combinatorial cancer therapy. Adv Mater 2025;37:e2503138.
111. Ferreira NH, Furtado RA, Ribeiro AB, de Oliveira PF, Ozelin SD, de Souza LDR, et al. Europium(III)-doped yttrium vanadate nanoparticles reduce the toxicity of cisplatin. J Inorg Biochem 2018;182:9-17.
112. Kulkarni-Dwivedi N, Patel PR, Shravage BV, Umrani RD, Paknikar KM, Jadhav SH. Hyperthermia and doxorubicin release by Fol-LSMO nanoparticles induce apoptosis and autophagy in breast cancer cells. Nanomedicine (Lond) 2022;17:1929-1949.
113. Kaliyamoorthy K, Pillai AS, Alexander A, Arivarasu A, Enoch I, Ramasamy S. β-Cyclodextrin-folate functionalized poly(lactic-co-glycolide)-superparamagnetic ytterbium ferrite hybrid nanocarrier for targeted delivery of camptothecin. Mater Sci Eng C Mater Biol Appl 2021;122:111796.
114. Koula G, Yakati V, Rachamalla HK, Bhamidipati K, Kathirvel M, Banerjee R, et al. Integrin receptor-targeted, doxorubicin-loaded cerium oxide nanoparticles delivery to combat glioblastoma. Nanomedicine (Lond) 2024;19:1389-1406.
115. Zhou X, You M, Wang F, Wang Z, Gao X, Jing C, et al. Multifunctional graphdiyne-cerium oxide nanozymes facilitate MicroRNA delivery and attenuate tumor hypoxia for highly efficient radiotherapy of esophageal cancer. Adv Mater 2021;33:e2100556.
116. Tian F, Xu C, Xu M, Gao H, Xiao Z, Li L, et al. DOX sensitized upconversion metal-organic frameworks for the pH responsive release and real-time detection of doxorubicin hydrochloride. RSC Adv 2020;10:33894-902.
117. Li PP, Yan Y, Zhang HT, Cui SH, Wang CH, Wei W, et al. Biological activities of siRNA-loaded lanthanum phosphate nanoparticles on colorectal cancer. J Control Release 2020;328:45-58.
118. Moaness M, Mousa SM, Abo-Elfadl MT, El-Bassyouni GT. Doxorubicin loaded cerium substituted hydroxyapatite nanoparticles: A promising new therapeutic approach for bone regeneration, doxorubicin delivery, and cancer treatment. Int J Pharm 2024;654:123969.
119. Sun X, Kou B. Biocompatibility and potential anticancer activity of gadolinium oxide (Gd2O3) nanoparticles against nasal squamous cell carcinoma. BMC Biotechnol 2024;24:53.
120.    Fang S, Zhang P, Chen X, Liu F, Wang F. Lanthanum chloride sensitizes cisplatin resistance of ovarian cancer cells via PI3K/Akt Pathway. Front Med (Lausanne) 2021;8:776876.
121. Wang F, Zhu Y, Fang S, Li S, Liu S. Lanthanum chloride enhances cisplatin-induced apoptosis in ovarian cancer cells. Cell Mol Biol (Noisy-le-grand) 2016;62:1-5.
122.    Wang F, Zhu Y, Fang S, Li S, Liu S. Effect of lanthanum chloride on tumor growth and apoptosis in human ovarian cancer cells and xenograft animal models. Exp Ther Med 2018;16:1143-1148.
123. Kater L, Kater B, Jakupec MA, Keppler BK, Prokop A. KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. J Biol Inorg Chem 2021;26:897-907.
124. Atlı Şekeroğlu Z, Şekeroğlu V, Aydın B, Kontaş Yedier S. Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxicity and activity against breast cancer cells. J Biomed Mater Res B Appl Biomater 2023;111:579-589.
125. Keramati Z, Motalleb G, Rahdar A, Kerachian MA. Anticancer effect of fluorouracil and gum-based cerium oxide nanoparticles on human malignant colon carcinoma cell line (Caco2). Cell J 2023;25:194-202.
126. Lu VM, Jue TR, McDonald KL. Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. Sci Rep 2020;10:18156.
127. Valimukhametova AR, Lee BH, Topkiran UC, Gries K, Gonzalez-Rodriguez R, Coffer JL, et al. Cancer therapeutic siRNA delivery and imaging by nitrogen- and neodymium-doped graphene quantum dots. ACS Biomater Sci Eng 2023;9:3425-3434.
128. Li X, Wang Y, Cao X, Song X, Chen L, Chang M, et al. Lanthanide-specific doping in vacancy-engineered piezocatalysts induces lysosomal destruction and tumor cell pyroptosis. J Nanobiotechnology 2025;23:331.
129. Zhao L, Zhang W, Wu Q, Fu C, Ren X, Lv K, et al. Lanthanide europium MOF nanocomposite as the theranostic nanoplatform for microwave thermo-chemotherapy and fluorescence imaging. J Nanobiotechnology 2022;20:133.
130. Mauro N, Cillari R, Gagliardo C, Utzeri MA, Marrale M, Cavallaro G. Gadolinium-doped carbon nanodots as potential anticancer tools for multimodal image-guided photothermal therapy and tumor monitoring. ACS Appl Nano Mater 2023;6:17206-17217.
131. Hu X, Tang Y, Hu Y, Lu F, Lu X, Wang Y, et al. Gadolinium-chelated conjugated polymer-based nanotheranostics for photoacoustic/magnetic resonance/NIR-II fluorescence imaging-guided cancer photothermal therapy. Theranostics 2019;9:4168-4181.
132. Santos JF, Laere CV, Silva CD, Cassells I, Fernandes C, Raposinho P, et al. Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161. EJNMMI Radiopharm Chem 2025;10:18.
133. Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. Combined gadolinium and boron neutron capture therapies for eradication of head-and-neck tumor using Gd10B6 nanoparticles under MRI/CT image guidance. JACS Au 2023;3:2192-2205.
134. Xie L, Qin J, Song C, Yin J, Wu R, Chen H, et al. 157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy. J Cancer Res Clin Oncol 2025;151:93.
135. Li F, Li Z, Jin X, Liu Y, Li P, Shen Z, et al. Radiosensitizing effect of gadolinium oxide nanocrystals in NSCLC cells under carbon ion irradiation. Nanoscale Res Lett 2019;14:328.
136. Costanzo M, Bianco S, Fik-Jaskółka M, Roviello GN. Recent advances in lanthanide complexes in biological systems: Coordination principles and interactions with biomolecules. Int J Mol Sci 2026;27:1566.
137. Constantin M, Chifiriuc MC, Vrancianu CO, Petrescu L, Cristian R-E, Crunteanu I, et al. Insights into the effects of lanthanides on mammalian systems and potential applications. EnvironRes 2024;263:120235.
138.    Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI contrast agents: Current challenges and new frontiers. Chem Rev 2019;119:957-1057.
139.    Casals E, Gusta MF, Piella J, Casals G, Jiménez W, Puntes V. Intrinsic and extrinsic properties affecting innate immune responses to nanoparticles: The case of cerium oxide. Front Immunol 2017; 8:970.
140. Cavalcanti IDL, Costa VcAF, Seixas DR, Neves BJ, Xavier-Junior FH, Lira Nogueira MCdB, et al. Activation of the complement system: Morphological differences in the surface of PIBCA nanoparticles coated with polysaccharides. ACS Nanoscience Au 2026;6:457-468.
141.    Gonzalez V, Vignati DAL, Leyval C, Giamberini L. Environmental fate and ecotoxicity of lanthanides: Are they a uniform group beyond chemistry? Environ Int 2014;71:148-157.
142.    Blinova I, Muna M, Heinlaan M, Lukjanova A, Kahru A. Potential hazard of lanthanides and lanthanide-based nanoparticles to aquatic ecosystems: Data gaps, challenges and future research needs derived from bibliometric analysis. Nanomaterials 2020;10:328.